具有T滤泡辅助表型的外周T细胞淋巴瘤的双重表观遗传学疗法加化疗。

IF 12.8 Q1 MEDICINE, RESEARCH & EXPERIMENTAL

Med Pub Date : 2024-11-08 DOI:10.1016/j.medj.2024.07.029

Suheil Albert Atallah-Yunes, Yucai Wang

{"title":"具有T滤泡辅助表型的外周T细胞淋巴瘤的双重表观遗传学疗法加化疗。","authors":"Suheil Albert Atallah-Yunes, Yucai Wang","doi":"10.1016/j.medj.2024.07.029","DOIUrl":null,"url":null,"abstract":"The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset.1 Further investigation into adding chemotherapy is warranted, building on the promising results seen in this trial.","PeriodicalId":29964,"journal":{"name":"Med","volume":"5 11","pages":"1335-1337"},"PeriodicalIF":12.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype.\",\"authors\":\"Suheil Albert Atallah-Yunes, Yucai Wang\",\"doi\":\"10.1016/j.medj.2024.07.029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset.1 Further investigation into adding chemotherapy is warranted, building on the promising results seen in this trial.\",\"PeriodicalId\":29964,\"journal\":{\"name\":\"Med\",\"volume\":\"5 11\",\"pages\":\"1335-1337\"},\"PeriodicalIF\":12.8000,\"publicationDate\":\"2024-11-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Med\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.medj.2024.07.029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.medj.2024.07.029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

Ding 等人进行的非随机 II 期研究探讨了在复发/难治性外周 T 细胞淋巴瘤中联合使用阿扎胞苷和千达酰胺以及 GemOx 化疗或不使用 GemOx 化疗的方法，结果表明这种双重表观遗传疗法安全有效，尤其是在血管免疫母细胞 T 细胞淋巴瘤亚群中1。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype.

The nonrandomized phase II study by Ding et al. explored the combination of azacitidine and chidamide with or without GemOx chemotherapy in relapsed/refractory peripheral T cell lymphoma and demonstrated that the dual epigenetic therapy is safe and efficacious, particularly in the angioimmunoblastic T cell lymphoma subset.¹ Further investigation into adding chemotherapy is warranted, building on the promising results seen in this trial.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Med MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

17.70

自引率

0.60%

发文量

102

期刊介绍： Med is a flagship medical journal published monthly by Cell Press, the global publisher of trusted and authoritative science journals including Cell, Cancer Cell, and Cell Reports Medicine. Our mission is to advance clinical research and practice by providing a communication forum for the publication of clinical trial results, innovative observations from longitudinal cohorts, and pioneering discoveries about disease mechanisms. The journal also encourages thought-leadership discussions among biomedical researchers, physicians, and other health scientists and stakeholders. Our goal is to improve health worldwide sustainably and ethically. Med publishes rigorously vetted original research and cutting-edge review and perspective articles on critical health issues globally and regionally. Our research section covers clinical case reports, first-in-human studies, large-scale clinical trials, population-based studies, as well as translational research work with the potential to change the course of medical research and improve clinical practice.